U.S. initiative grapples with ethical questions on brain research
Khara Ramos explains how the Brain Initiative incorporates the emerging field of ‘neuroethics’ into the research it funds.
Conversations with experts about noteworthy topics in autism.
Khara Ramos explains how the Brain Initiative incorporates the emerging field of ‘neuroethics’ into the research it funds.
Molecular biologist Jonathan Mill is probing gene expression’s role in autism in uncharted territory — the fetal human brain.
Researcher Randi Hagerman is a big proponent of metformin — a diabetes drug that she is testing in people with fragile X syndrome. In fact, Hagerman takes the drug herself as a preventive measure against cancer.
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Katie Carey, who has illustrated several Spectrum articles, reveals her creative process and her strategies for pushing past mental blocks.
How researchers design autism prevalence studies has a significant impact on the results, says Eric Fombonne.
Genes linked to autism are critical to the development of star-shaped brain cells called astrocytes, suggesting a key role for the cells in the condition.
Sally Ozonoff is looking for early signs of attention deficit hyperactivity disorder in videos of hundreds of younger siblings of children with autism.
Autism researchers need no longer worry that their basic research will become entangled in the red tape associated with clinical trials.
Scanning the brains of a single individual over months to years may illuminate daily fluctuations in activity relevant to conditions such as autism, says Russell Poldrack.